The National Cancer Institute Study of Tamoxifen and Raloxifene (STAR) Trial has just concluded. It was one of the largest breast cancer prevention studies ever. It found that raloxifene, which is usually used for osteoporosis, is as effective as tamoxifen in preventing breast cancer in post-menopausal women who are at high risk of breast cancer. Raloxifene also had fewer side effects.

This study has generated much press attention and is sure to impact the lives of thousands of women who are currently taking tamoxifen. You may review the STAR Trial home page here, or read this Reuters article about the results.